Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
ProMIS Neurosciences Inc
PMN
Healthcare
Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational...
discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:PMN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(107)
•••
Gbathat
X
Post by
Gbathat
on May 23, 2025 7:09pm
position
If all goes to plan, I should own 0.1% of the company stock by Monday
(23)
•••
Speyeder999
X
Comment by
Speyeder999
on May 23, 2025 9:01am
RE:RE:RE:Donkeys
Among many questions, delisting seems like a legitimite one to ask directors at the AGM in June. Now to see if they will actually begin answering them.....
(37)
•••
Blueknowser1
X
Comment by
Blueknowser1
on May 22, 2025 2:21pm
RE:RE:Donkeys
Well, the press release basically said nothing and the shorts continue to manipulate the stock; with a delisting fast approaching!
(5)
•••
retiredcop
X
Post by
retiredcop
on May 19, 2025 5:11pm
More research on ARIA
In Clinical Use, Most ARIA Occurs in People With Dementia, Not MCI | ALZFORUM
•••
Jonathon Brown
X
Post by
Jonathon Brown
on May 15, 2025 8:58am
Buzz on the Bullboards: Quarterly reports and company mergers
This week also marks the heart of quarterly earnings season, when companies disclose their financial and operational performance.
read article.
(23)
•••
Speyeder999
X
Post by
Speyeder999
on May 14, 2025 3:23pm
Maxim Group
https://www.nasdaq.com/articles/maxim-group-initiates-coverage-promis-neurosciences-pmn-buy-recommendation
(52)
•••
M101
X
Post by
M101
on May 14, 2025 12:07pm
better detection coming
cheap test tech from China, or at least cheap outside the US https://english.news.cn/20250405/a829476195bb40a69c70b8cf695988af/c.html
(107)
•••
Gbathat
X
Comment by
Gbathat
on May 12, 2025 7:16pm
RE:New Press Release - ProMIS Neurosciences Announces First Quarter 2025 Financial Results
"The pace of enrollment exceeded our expectations, reflecting the growing enthusiasm from investigators for PMN310’s differentiated profile"
(27)
•••
FarmerBetsy
X
Comment by
FarmerBetsy
on May 12, 2025 8:07am
RE:Couple of Thoughts
Your making me add more BUTTER to the popcorn. Not fooled by your Proxy ownership numbers. Not news but repricing options may double the price of the stock? The Nasdaq roars, Promis repriced
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on May 12, 2025 7:30am
New Press Release - ProMIS Neurosciences Announces First Quarter 2025 Financial Results
First Cohort Completed in PRECISE-AD Trial Evaluating PMN310 in Alzheimer’s Disease Six Month Interim Results Expected in 1H 2026 Topline Results Anticipated by end of 2026CAMBRIDGE, Massachusetts, May 12, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage...
read article.
(116)
•••
bball67
X
Post by
bball67
on May 11, 2025 10:40pm
Couple of Thoughts
Proxy shows 5 shareholders at 9.99% ownership, one at 8% and board and mgmt at 6% which is 64% controlled by a few. Proposal 3 is the 2025 stock option plan which has a provision on page 42
...more
(27)
•••
FarmerBetsy
X
Comment by
FarmerBetsy
on May 11, 2025 4:44pm
RE:RE:Coming to an End
Gbathat and BBall just a little butter on the popcorn not to much!!!
(107)
•••
Gbathat
X
Comment by
Gbathat
on May 10, 2025 5:11pm
RE:Coming to an End
Please sell me your shares on Monday. Thanks.
(27)
•••
FarmerBetsy
X
Post by
FarmerBetsy
on May 10, 2025 3:30pm
Coming to an End
Promis is controlled by just a couple of shareholders. Yes I know a few Institutional just below 30% of stock, then the remainder of owners very very low. Promis is on the way out, bust, private or
...more
(10)
•••
Alex1726
X
Post by
Alex1726
on May 08, 2025 5:12pm
ANAVEX (AVXL)
I already mentionned that name but if you want to make money in the CNS research your best bet is ANAVEX LIFE SCIENCES. Take a look it worth it.
(10)
•••
Alex1726
X
Post by
Alex1726
on May 08, 2025 5:08pm
End is coming.
In a year from now i would be very surprise if they still exist , they'll miss cash and in the context we're in now it won't be easy to find some. It will be the end soon. It could have
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Developing a sizeable copper resource with a highly prospective exploration asset in Peru
Identifying new compelling targets on extensive and highly prospective land position